Aug 5 (Reuters) - Allurion Technologies Inc ALUR.N:
ALLURION ANNOUNCES NEW STRATEGIC DIRECTION WITH INCREASING FOCUS ON LOW-DOSE GLP-1 COMBINATION THERAPY, MUSCLE MASS MAINTENANCE, AND US MARKET ENTRY
ALLURION TECHNOLOGIES INC - EXPECTS Q2 2025 REVENUE OF $3 MILLION, LOSS OF $7 MILLION
Source text: ID:nBw9FqVV1a
Further company coverage: ALUR.N
((Reuters.Briefs@thomsonreuters.com;))